AR067639A1 - Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente - Google Patents

Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente

Info

Publication number
AR067639A1
AR067639A1 ARP080103160A ARP080103160A AR067639A1 AR 067639 A1 AR067639 A1 AR 067639A1 AR P080103160 A ARP080103160 A AR P080103160A AR P080103160 A ARP080103160 A AR P080103160A AR 067639 A1 AR067639 A1 AR 067639A1
Authority
AR
Argentina
Prior art keywords
well
excipient
lactose
tiotropy
salmetrol
Prior art date
Application number
ARP080103160A
Other languages
English (en)
Spanish (es)
Inventor
Stephanie Ossadnik
Michael Trunk
Michael Walz
Christoph Kreher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR067639A1 publication Critical patent/AR067639A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A61M15/0026—Hinged caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080103160A 2007-07-21 2008-07-21 Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente AR067639A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007034157 2007-07-21
US5193308P 2008-05-09 2008-05-09

Publications (1)

Publication Number Publication Date
AR067639A1 true AR067639A1 (es) 2009-10-21

Family

ID=39869109

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103160A AR067639A1 (es) 2007-07-21 2008-07-21 Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente

Country Status (9)

Country Link
US (1) US20100189780A1 (enExample)
EP (1) EP2182933B1 (enExample)
JP (1) JP2011509919A (enExample)
AR (1) AR067639A1 (enExample)
CA (1) CA2694479C (enExample)
PE (1) PE20090907A1 (enExample)
TW (1) TW200909004A (enExample)
UY (1) UY31235A1 (enExample)
WO (1) WO2009013244A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100638936B1 (ko) * 2005-03-31 2006-10-25 엘지전자 주식회사 건조기의 캐비닛 구조
HUE067290T2 (hu) 2009-02-26 2024-10-28 Glaxo Group Ltd 4-{(1 R)-2-[(6-{2-[(2,6-diklórbenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroxi-metil)fenolt tartalmazó gyógyszerkészítmények
EP2277799B8 (en) * 2009-07-23 2012-04-11 Airsec S.A.S. Hydrated humidity control substance and process for its preparation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
MD4117C1 (ro) * 2010-07-30 2012-02-29 Институт Химии Академии Наук Молдовы Pudră cu capacitate hemostatică şi regenerativă (variante) şi procedeu de obţinere a acesteia
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP3461474B1 (en) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ITMI20120092A1 (it) * 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
US8545878B1 (en) 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
EP2934594B1 (en) 2012-12-18 2019-09-04 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities .
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
AR102305A1 (es) * 2014-10-16 2017-02-15 Teva Branded Pharmaceutical Products R&D Inc Procedimiento para preparar formulación farmacéutica inhalable de polvo seco
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
CA169756S (en) 2016-02-08 2017-09-01 Nicoventures Holdings Ltd Electronic cigarette
GB201605102D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Mechanical connector for electronic vapour provision system
GB201605100D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision system
GB201605101D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Electronic vapour provision system
GB201605105D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision apparatus
CN109476408A (zh) 2016-07-22 2019-03-15 尼科创业控股有限公司 蒸汽供应装置外壳
PL3833964T3 (pl) * 2018-08-07 2023-09-04 Norton (Waterford) Limited Zastosowanie spektroskopii ramana do produkcji proszków do inhalacji
PL244452B1 (pl) * 2020-08-24 2024-01-29 Pulinno Spolka Z Ograniczona Odpowiedzialnoscia Inhalator kapsułkowy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002822L (sv) * 2000-08-04 2002-01-29 Microdrug Ag Elektropulver
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
UA83813C2 (ru) * 2002-12-20 2008-08-26 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler

Also Published As

Publication number Publication date
JP2011509919A (ja) 2011-03-31
CA2694479C (en) 2016-09-13
US20100189780A1 (en) 2010-07-29
EP2182933B1 (de) 2016-09-07
CA2694479A1 (en) 2009-01-29
WO2009013244A1 (de) 2009-01-29
TW200909004A (en) 2009-03-01
EP2182933A1 (de) 2010-05-12
UY31235A1 (es) 2009-03-02
PE20090907A1 (es) 2009-08-05

Similar Documents

Publication Publication Date Title
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
HK1203149A1 (en) Novel dosage form and formulation of abediterol
ECSP055855A (es) Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
PE20160853A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
PE20091691A1 (es) Formulacion para inhalacion que comprende aclidinio
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
CL2009000602A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclidinio equivalente a aproximadamente 400 microgramos de bromuro de aclidinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
EP2682108A3 (en) Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
NZ627837A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
CL2011002002A1 (es) Uso de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1- hidroxietil)-8-hidroxiquinolin-2-(1h)-ona, en forma de racemato, estereoisomero o mezclas de esteroisomeros o una sal o solvato del mismo para preparar un medicamento util para tratar una enfermedad pulmonar.
NO20051956L (no) Salmeterol superfin formulering
UY28589A1 (es) Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen
WO2015049519A3 (en) Method and apparatus for making compositions for pulmonary administration
UY28590A1 (es) Procedimiento para la preparación de nuevas sales de tiotropio, nuevas sales de tiotropio como tales, así como las formulaciones medicamentosas que las contienen.
MX373699B (es) Composicion farmaceutica que contiene budesonida y formoterol.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
ECSP055821A (es) Nueva formulacion pulverulenta que contiene tiotropio destinado a la inhalación
MX372705B (es) Composición farmacéutica que contiene budesonida y formoterol
TR200909788A2 (tr) Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
TH147031A (th) ขนาดการให้ยาและสูตรผสมชนิดใหม่
CL2008002135A1 (es) Polvos inhalables que contienen el excipiente lactosa, una sal de adicion de salmeterol y una sal de tiotropio que presenta un valor de aw de entre 0,05 y 0,5; composicion farmaceutica que lo comprende; procedimiento de preparacion de dichos polvos; kit de inhalacion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure